An investigator-sponsored clinical trial of DKN-01 in patients with advanced hepatocellular carcinoma (HCC) with activated Wnt signaling.
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2018
At a glance
- Drugs DKN 01 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms DIAL-1
- 09 Nov 2018 According to a Leap Therapeutics media release, first patient has been enrolled in this study.
- 09 Nov 2018 Status changed from planning to recruiting, according to a Leap Therapeutics media release.
- 23 Feb 2018 According to a Leap Therapeutics media release, enrollment of first patient is anticipated in 2018.